Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights

Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers

(2016) Chang Gon Kim et al.   BRITISH JOURNAL OF CANCER

Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies

(2016) D. Azuara et al.   MOLECULAR CANCER THERAPEUTICS

Adequately defining tumor cell proportion in tissue samples for molecular testing improves interobserver reproducibility of its assessment

(2016) Benoît Lhermitte et al.   VIRCHOWS ARCHIV

Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection

(2016) Anita Sveen et al.   PLoS Genetics

Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial

(2015) N. Normanno et al.   ANNALS OF ONCOLOGY

Clonal status of actionable driver events and the timing of mutational processes in cancer evolution

(2015) Nicholas McGranahan et al.   Science Translational Medicine

Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer

(2015) Muhammed Murtaza et al.   Nature Communications

Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer

(2015) M. Russo et al.   Cancer Discovery

Mutant allele frequency predicts the efficacy of EGFR-TKIs in lung adenocarcinoma harboring the L858R mutation

(2014) A. Ono et al.   ANNALS OF ONCOLOGY

Clinical Relevance of KRAS-Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy

(2014) P. Laurent-Puig et al.   CLINICAL CANCER RESEARCH

Pan-cancer patterns of somatic copy number alteration

(2013) Travis I Zack et al.   NATURE GENETICS

Molecular Profiling of Patients with Colorectal Cancer and Matched Targeted Therapy in Phase I Clinical Trials

(2012) R. Dienstmann et al.   MOLECULAR CANCER THERAPEUTICS

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

(2012) Anirudh Prahallad et al.   NATURE

Comprehensive molecular characterization of human colon and rectal cancer

(2012)   NATURE

Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer

(2011) Qing Zhou et al.   JOURNAL OF CLINICAL ONCOLOGY